Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RS2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Transoral Suturing |
| Name | Type | Description |
|---|---|---|
| RS2 (RESTORe Suturing System) | DEVICE | Suturing in stomach |
Inclusion Criteria: * Male, Female; ages \>18yrs - £ 60 yrs * BMI 30-45 kg/m2 * History of obesity for 5 yrs; attempts at weight control ineffective * Weight stable * Willing to comply with study requirements * Agrees to not have any additional weight loss surgery, reconstructive surgery or liposuc...
Top 20 of 32 competitors
RS2 is an investigational therapy being studied for the treatment of obesity. It is currently in Phase 1 clinical development. The drug is being developed by Becton, Dickinson and Company, a medical technology company.
RS2 is being developed by Becton, Dickinson and Company, which trades under the ticker BDX. The company is conducting clinical research on this investigational drug for obesity. RS2 is currently in Phase 1 development.
RS2 is in Phase 1 clinical development. It is an investigational drug being studied for obesity and has not been approved by regulatory authorities. One Phase 1 clinical trial for RS2 has been completed.
RS2 has one completed Phase 1 clinical trial, identified as NCT00679848, titled "Transoral Gastric Volume Reduction as an Intervention for Weight Management." This trial enrolled 18 participants with obesity in the United States and was not randomized or blinded.
RS2 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for obesity. The drug has completed one early-stage clinical trial, but it remains under investigation and has not received regulatory approval.